Amgen Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Amgen de 8.9% y 4.4% por año respectivamente. Se prevé que el BPA crezca en un 10.4% al año. Se espera que la rentabilidad financiera sea de 379.7% en 3 años.

Información clave

18.9%

Tasa de crecimiento de los beneficios

19.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	3.5%
Rentabilidad financiera futura	505.1%
Cobertura de analistas	Good
Última actualización	03 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

Feb 08

Amgen: Accelerating The Business And Dividend Growth

Jan 29

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Jan 29

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Jan 22

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Dec 28

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Dec 13

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Oct 23

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Sep 22

Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?

Sep 04

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Aug 05

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 30

Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

May 09

These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well

Apr 29

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Apr 05

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 37% Below Their Intrinsic Value Estimate

Feb 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:AMGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	34,796	7,418	13,033	13,883	22
12/31/2025	34,070	6,960	12,760	13,784	27
12/31/2024	33,011	4,272	15,165	15,110	27
3/31/2024	29,532	3,763	7,098	8,096	N/A
12/31/2023	28,190	6,717	7,359	8,471	N/A
9/30/2023	26,833	7,566	9,379	10,582	N/A
6/30/2023	26,582	7,979	9,685	10,800	N/A
3/31/2023	26,190	7,917	7,531	8,621	N/A
12/31/2022	26,323	6,552	8,785	9,721	N/A
9/30/2022	26,330	6,835	8,997	9,880	N/A
6/30/2022	26,384	6,576	8,355	9,320	N/A
3/31/2022	26,316	5,723	8,417	9,321	N/A
12/31/2021	25,979	5,893	8,381	9,261	N/A
9/30/2021	25,767	5,609	7,840	8,606	N/A
6/30/2021	25,484	5,746	8,897	9,556	N/A
3/31/2021	25,164	7,085	9,835	10,467	N/A
12/31/2020	25,424	7,264	9,889	10,497	N/A
9/30/2020	24,987	7,352	10,235	10,858	N/A
6/30/2020	24,301	7,299	10,209	10,867	N/A
3/31/2020	23,966	7,675	8,795	9,439	N/A
12/31/2019	23,362	7,842	8,532	9,150	N/A
9/30/2019	23,395	8,067	9,175	9,830	N/A
6/30/2019	23,562	7,958	9,070	9,726	N/A
3/31/2019	23,750	8,075	9,715	10,414	N/A
12/31/2018	23,747	8,394	10,558	11,296	N/A
9/30/2018	23,319	2,202	10,448	11,114	N/A
6/30/2018	23,188	2,364	10,642	11,295	N/A
3/31/2018	22,939	2,219	10,868	11,519	N/A
12/31/2017	22,849	1,979	N/A	11,177	N/A
9/30/2017	23,012	8,178	N/A	11,265	N/A
6/30/2017	23,050	8,174	N/A	10,473	N/A
3/31/2017	22,928	7,893	N/A	10,824	N/A
12/31/2016	22,991	7,722	N/A	10,354	N/A
9/30/2016	22,562	7,587	N/A	9,327	N/A
6/30/2016	22,474	7,433	N/A	9,557	N/A
3/31/2016	22,156	7,216	N/A	10,164	N/A
12/31/2015	21,662	6,939	N/A	9,731	N/A
9/30/2015	21,457	6,433	N/A	10,103	N/A
6/30/2015	20,765	5,814	N/A	9,952	N/A
3/31/2015	20,575	5,708	N/A	8,895	N/A
12/31/2014	20,063	5,158	N/A	8,952	N/A
9/30/2014	19,743	4,885	N/A	7,945	N/A
6/30/2014	19,460	5,009	N/A	7,011	N/A
3/31/2014	18,959	4,720	N/A	6,384	N/A
12/31/2013	18,676	5,081	N/A	6,291	N/A
9/30/2013	17,980	4,848	N/A	5,268	N/A
6/30/2013	17,551	4,587	N/A	5,184	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (8.9% al año) de AMGN es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (29.3% al año) de AMGN crezcan más rápidamente que el mercado US (14.1% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de AMGN crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (4.4% al año) de AMGN crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.4% al año) de AMGN crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AMGN sea muy elevada dentro de 3 años (379.7%).

Amgen Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates fall by 20%

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Consensus EPS estimates fall by 12%

Recent updates

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen: The Giant With An Impressive Pipeline

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Amgen Will Benefit From Increased Medical Spending

Dividend of US$2.25 announced

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen: A Good Dividend Growth Stock For The Watch List

Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Consensus EPS estimates fall by 20%

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

New minor risk - Earnings quality

Upcoming dividend of US$2.25 per share at 3.0% yield

Full year 2023 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen: Accelerating The Business And Dividend Growth

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Executive VP recently sold US$2.7m worth of stock

Executive VP notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.1% yield

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Insider recently sold US$2.5m worth of stock

Insider notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.3% yield

Amgen Inc. Announces Management Changes

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Upcoming dividend of US$2.13 per share at 3.6% yield

Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind